An overview of using fungal DNA for the diagnosis of invasive mycoses.


Journal

Expert review of molecular diagnostics
ISSN: 1744-8352
Titre abrégé: Expert Rev Mol Diagn
Pays: England
ID NLM: 101120777

Informations de publication

Date de publication:
Feb 2022
Historique:
pubmed: 8 2 2022
medline: 2 4 2022
entrez: 7 2 2022
Statut: ppublish

Résumé

Fungal PCR has undergone considerable standardization and, together with the availability of commercial assays, external quality assessment schemes, and extensive performance validation data, is ready for widespread use for the screening and diagnosis of invasive fungal disease (IFD). Drawing on the experience and knowledge of the leads of the various working parties of the Fungal PCR initiative, this review will address general considerations concerning the use of molecular tests for the diagnosis of IFD, before focusing specifically on the technical and clinical aspects of molecular testing for the main causes of IFD and recent technological developments. For infections caused by

Identifiants

pubmed: 35130460
doi: 10.1080/14737159.2022.2037423
doi:

Substances chimiques

DNA, Fungal 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

169-184

Auteurs

P Lewis White (PL)

Public Health Wales Microbiology Cardiff, UHW, Cardiff, UK.

Alexandre Alanio (A)

Laboratoire de Parasitologie-Mycologie, Groupe Hospitalier Lariboisière, Saint-Louis, Fernand Widal, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.
Université de Paris, Paris, France.
Institut Pasteur, CNRS UMR2000, Unité de Mycologie Moléculaire, Centre National de Reference Mycoses invasives et Antifongiques, Paris, France.

Lottie Brown (L)

NHS Mycology Reference Centre Manchester, ECMM Centre of Excellence, Manchester University NHS Foundation Trust, Wythenshawe Hospital; and Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, UK.

Mario Cruciani (M)

Fungal PCR Initiative, Nijmegen, The Netherlands.

Ferry Hagen (F)

Westerdijk Fungal Biodiversity Institute, Utrecht, The Netherlands & Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands.

Rebecca Gorton (R)

Department of Infection Sciences, Health Services Laboratories (HSL) LLP, London, UK.

Michaela Lackner (M)

Institute of Hygiene and Medical Microbiology, Department of Hygiene, Medical Microbiology and Publics Health, Medical University Innsbruck, Innsbruck, Austria.

Laurence Millon (L)

Parasitology-Mycology Department, University Hospital of Besançon, Besançon, France.
UMR 6249 CNRS Chrono-Environnement, University of Bourgogne Franche-Comté, Besançon, France.

C Oliver Morton (CO)

School of Science, Western Sydney University, Campbelltown, Australia.

Riina Rautemaa-Richardson (R)

NHS Mycology Reference Centre Manchester, ECMM Centre of Excellence, Manchester University NHS Foundation Trust, Wythenshawe Hospital; and Division of Infection, Immunity and Respiratory Medicine, Faculty of Biology, Medicine and Health, University of Manchester, UK.

Rosemary A Barnes (RA)

Cardiff University, Cardiff, UK.

J Peter Donnelly (JP)

Fungal PCR Initiative, Nijmegen, The Netherlands.

Juergen Loffler (J)

Department of Internal Medicine II, WÜ4i, University Hospital Wuerzburg, Wuerzburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH